The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma (msn.com)
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $124.8M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $21.83K | 212.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 443503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 424264 | 6 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| ALA (ASX) Chart |